Study to Determine the Efficacy, Safety, Tolerability & Pharmacokinetics of RO 205-2349 in Patients With Type 2 Diabetes Mellitus
NCT00057304
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
190
Enrollment
INDUSTRY
Sponsor class
Conditions
Diabetes
Interventions
DRUG:
RO 205-2349
Sponsor
Hoffmann-La Roche